US Federal 2025-2026 Regular Session

US Federal Senate Bill SB2336

Introduced
7/17/25  

Caption

Halting the Epidemic of Addiction and Loss Act of 2025

Impact

The enacted provisions of SB2336 will specifically influence federal grant programs designed to combat opioid misuse. These updates will be mandatory, ensuring that any future regulations or guidance by the HHS are mindful of a broader range of opioid overdose reversal drugs. As a result, states and tribal entities will potentially gain access to a wider variety of treatment options, which could lead to improved outcome rates in overdose situations and a more robust response to the opioid epidemic. This bill signifies a step towards adapting health policies to the evolving landscape of substance use treatment options.

Summary

SB2336, known as the 'Halting the Epidemic of Addiction and Loss Act of 2025', focuses on ensuring that references to opioid overdose reversal agents in certain grant programs from the Department of Health and Human Services (HHS) are not limited to naloxone. The bill emphasizes the need for broader inclusion of other approved overdose reversal drugs, which are vital in combating the opioid crisis affecting various communities in the United States. By updating guidelines to ensure inclusivity in grant programs, the bill aims to enhance the effectiveness of funding aimed at addressing opioid misuse and substance use disorders.

Contention

The primary point of contention surrounding SB2336 revolves around the adequacy of current overdose reversal measures and whether naloxone, while widely recognized, is sufficient to address the complex nature of opioid overdoses. Critics may argue that a reliance on a single drug could create a false sense of security regarding recovery measures available in crisis situations. Furthermore, the bill may provoke discussions on how effectively these updated guidelines can be translated into practice, particularly regarding education and training for first responders and community members involved in overdose management.

Companion Bills

US HB2483

Related SUPPORT for Patients and Communities Reauthorization Act of 2025

Previously Filed As

US HR512

House Study Committee on the Addiction Epidemic and Solutions for Recovery; create

US HB05515

An Act Concerning The Department Of Mental Health And Addiction Services' Recommendations Regarding Access To Opioid Overdose Reversal Medication And Various Revisions To Mental Health And Addiction Statutes.

US HF584

A bill for an act relating to the opioid settlement fund, establishing the opioid epidemic response advisory council, making appropriations, and including effective date provisions.

US SB43

Substance use disorder: addiction treatment referral agencies.

US SB909

In powers and duties of the Department of Drug and Alcohol Programs, further providing for regulatory flexibility during opioid epidemic.

US HB2483

SUPPORT for Patients and Communities Reauthorization Act of 2025

US SB0403

Health occupations: pharmacists; dispensing certain addiction medications without undue delay; require. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7333c.

US HB4977

EPIDEMIOLOGICAL PATHOGENS

US HR671

Prioritizing mental health to the same degree as physical health to address the epidemics of suicide and drug overdose in the United States.

US S3079

"HOPE Initiative Act"; requires establishment of public awareness campaign to educate citizens about dangers and causes of, and appropriate responses to, heroin and opioid addiction.

Similar Bills

No similar bills found.